adozelesin and Uterine-Neoplasms

adozelesin has been researched along with Uterine-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for adozelesin and Uterine-Neoplasms

Article	Year
In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines. Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:1 Adozelesin is a derivative of an extremely cytotoxic compound, CC1065. This entirely new class of drug binds preferentially to DNA and facilitates alkylation reaction. In the present study, we used the adenosine triphosphate (ATP) chemosensitivity assay to compare the cytotoxic potency of Adozelesin with that of common chemotherapeutic agents in ten gynecologic-cancer cell lines. Flow cytometry was also used to study its effects on cell-cycle kinetics. The mean drug concentrations required to produce a 50% reduction in ATP levels as compared with controls [IC50] were: Adriamycin, 0.17 +/- 0.06 microM; 4OH-Cytoxan, 18 +/- 3 microM; cisplatin, 17 +/- 7 microM; 5-fluorouracil, 183 +/- 116 microM; and Adozelesin, 11.0 +/- 5.4 pM. Thus, Adozelesin was 10(4) - 10(7) times more potent than Adriamycin, cisplatin, 5-fluorouracil, and Cytoxan. Cell kinetics studies revealed significant S and G2 blocks such as those previously reported for other alkylating agents. Topics: Adenocarcinoma; Antineoplastic Agents; Benzofurans; Cell Cycle; Cyclohexanecarboxylic Acids; Cyclohexenes; Drug Screening Assays, Antitumor; Duocarmycins; Female; Genital Neoplasms, Female; Humans; Indoles; Kinetics; Tumor Cells, Cultured; Uterine Neoplasms	1992

Article

Year

In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:1

Adozelesin is a derivative of an extremely cytotoxic compound, CC1065. This entirely new class of drug binds preferentially to DNA and facilitates alkylation reaction. In the present study, we used the adenosine triphosphate (ATP) chemosensitivity assay to compare the cytotoxic potency of Adozelesin with that of common chemotherapeutic agents in ten gynecologic-cancer cell lines. Flow cytometry was also used to study its effects on cell-cycle kinetics. The mean drug concentrations required to produce a 50% reduction in ATP levels as compared with controls [IC50] were: Adriamycin, 0.17 +/- 0.06 microM; 4OH-Cytoxan, 18 +/- 3 microM; cisplatin, 17 +/- 7 microM; 5-fluorouracil, 183 +/- 116 microM; and Adozelesin, 11.0 +/- 5.4 pM. Thus, Adozelesin was 10(4) - 10(7) times more potent than Adriamycin, cisplatin, 5-fluorouracil, and Cytoxan. Cell kinetics studies revealed significant S and G2 blocks such as those previously reported for other alkylating agents.

Topics: Adenocarcinoma; Antineoplastic Agents; Benzofurans; Cell Cycle; Cyclohexanecarboxylic Acids; Cyclohexenes; Drug Screening Assays, Antitumor; Duocarmycins; Female; Genital Neoplasms, Female; Humans; Indoles; Kinetics; Tumor Cells, Cultured; Uterine Neoplasms

1992